Annual SG&A
$113.98 M
+$65.90 M+137.05%
31 December 2023
Summary:
Lexicon Pharmaceuticals annual selling, general & administrative expenses is currently $113.98 million, with the most recent change of +$65.90 million (+137.05%) on 31 December 2023. During the last 3 years, it has risen by +$66.75 million (+141.33%). LXRX annual SG&A is now at all-time high.LXRX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$39.59 M
+$400.00 K+1.02%
30 September 2024
Summary:
Lexicon Pharmaceuticals quarterly selling, general & administrative expenses is currently $39.59 million, with the most recent change of +$400.00 thousand (+1.02%) on 30 September 2024. Over the past year, it has increased by +$7.36 million (+22.85%). LXRX quarterly SG&A is now at all-time high.LXRX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$7.38 B
-$216.39 M-3.02%
30 September 2024
Summary:
Lexicon Pharmaceuticals TTM selling, general & administrative expenses is currently -$7.38 billion, with the most recent change of -$216.39 million (-3.02%) on 30 September 2024. Over the past year, it has dropped by -$7.48 billion (-7657.66%). LXRX TTM SG&A is now -17345.76% below its all-time high of $143.45 million, reached on 30 September 2024.LXRX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LXRX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +137.1% | +22.9% | -7657.7% |
| 3 y3 years | +141.3% | +442.1% | -10000.0% |
| 5 y5 years | +78.8% | +184.9% | -10000.0% |
LXRX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +252.4% | at high | +442.1% | -29.1% | at low |
| 5 y | 5 years | at high | +252.4% | at high | +515.5% | -33.9% | at low |
| alltime | all time | at high | +3830.4% | at high | +948.8% | <-9999.0% | at low |
Lexicon Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $39.59 M(+1.0%) | $143.45 M(+5.4%) |
| June 2024 | - | $39.19 M(+22.2%) | $136.09 M(+7.2%) |
| Mar 2024 | - | $32.06 M(-1.7%) | $126.90 M(+11.3%) |
| Dec 2023 | $113.98 M(+137.1%) | $32.61 M(+1.2%) | $113.98 M(+16.7%) |
| Sept 2023 | - | $32.23 M(+7.4%) | $97.70 M(+25.2%) |
| June 2023 | - | $30.01 M(+56.8%) | $78.05 M(+32.9%) |
| Mar 2023 | - | $19.14 M(+17.2%) | $58.73 M(+22.1%) |
| Dec 2022 | $48.08 M(+48.7%) | $16.33 M(+29.8%) | $48.08 M(+18.4%) |
| Sept 2022 | - | $12.58 M(+17.7%) | $40.60 M(+14.9%) |
| June 2022 | - | $10.69 M(+25.9%) | $35.33 M(+8.4%) |
| Mar 2022 | - | $8.49 M(-4.0%) | $32.58 M(+0.7%) |
| Dec 2021 | $32.34 M(-31.5%) | $8.85 M(+21.1%) | $32.34 M(+8.1%) |
| Sept 2021 | - | $7.30 M(-8.0%) | $29.93 M(-13.6%) |
| June 2021 | - | $7.94 M(-3.9%) | $34.62 M(-15.1%) |
| Mar 2021 | - | $8.26 M(+28.4%) | $40.80 M(-13.6%) |
| Dec 2020 | $47.23 M(-16.9%) | $6.43 M(-46.4%) | $47.23 M(-14.7%) |
| Sept 2020 | - | $12.00 M(-15.0%) | $55.36 M(-3.3%) |
| June 2020 | - | $14.11 M(-3.9%) | $57.26 M(-0.3%) |
| Mar 2020 | - | $14.69 M(+0.9%) | $57.41 M(+1.0%) |
| Dec 2019 | $56.84 M(-10.9%) | $14.56 M(+4.8%) | $56.84 M(-3.4%) |
| Sept 2019 | - | $13.90 M(-2.6%) | $58.83 M(-2.8%) |
| June 2019 | - | $14.26 M(+1.1%) | $60.52 M(-4.0%) |
| Mar 2019 | - | $14.11 M(-14.8%) | $63.01 M(-1.2%) |
| Dec 2018 | $63.75 M(-3.5%) | $16.56 M(+6.3%) | $63.75 M(+0.9%) |
| Sept 2018 | - | $15.58 M(-7.0%) | $63.21 M(-1.8%) |
| June 2018 | - | $16.75 M(+12.8%) | $64.36 M(-2.6%) |
| Mar 2018 | - | $14.86 M(-7.3%) | $66.08 M(-0.0%) |
| Dec 2017 | $66.09 M(+53.1%) | $16.02 M(-4.2%) | $66.09 M(+3.0%) |
| Sept 2017 | - | $16.72 M(-9.5%) | $64.15 M(+7.5%) |
| June 2017 | - | $18.48 M(+24.2%) | $59.69 M(+20.3%) |
| Mar 2017 | - | $14.87 M(+5.6%) | $49.63 M(+15.0%) |
| Dec 2016 | $43.16 M(+81.1%) | $14.08 M(+14.8%) | $43.16 M(+21.5%) |
| Sept 2016 | - | $12.26 M(+45.7%) | $35.52 M(+24.0%) |
| June 2016 | - | $8.42 M(+0.2%) | $28.64 M(+7.9%) |
| Mar 2016 | - | $8.40 M(+30.2%) | $26.53 M(+11.3%) |
| Dec 2015 | $23.84 M(+22.8%) | $6.45 M(+19.9%) | $23.84 M(+11.5%) |
| Sept 2015 | - | $5.38 M(-14.7%) | $21.38 M(+3.7%) |
| June 2015 | - | $6.31 M(+10.6%) | $20.61 M(+5.9%) |
| Mar 2015 | - | $5.70 M(+43.0%) | $19.46 M(+0.2%) |
| Dec 2014 | $19.41 M(+13.4%) | $3.99 M(-13.6%) | $19.41 M(+3.1%) |
| Sept 2014 | - | $4.62 M(-10.4%) | $18.84 M(-0.5%) |
| June 2014 | - | $5.15 M(-8.9%) | $18.93 M(+2.6%) |
| Mar 2014 | - | $5.65 M(+65.7%) | $18.45 M(+7.8%) |
| Dec 2013 | $17.12 M(+0.5%) | $3.41 M(-27.7%) | $17.12 M(-2.9%) |
| Sept 2013 | - | $4.72 M(+1.0%) | $17.63 M(+1.8%) |
| June 2013 | - | $4.67 M(+8.0%) | $17.31 M(+3.0%) |
| Mar 2013 | - | $4.32 M(+10.3%) | $16.80 M(-1.4%) |
| Dec 2012 | $17.04 M | $3.92 M(-10.8%) | $17.04 M(-0.5%) |
| Sept 2012 | - | $4.40 M(+5.6%) | $17.13 M(+2.0%) |
| June 2012 | - | $4.16 M(-8.8%) | $16.79 M(-2.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $4.57 M(+13.8%) | $17.16 M(-1.1%) |
| Dec 2011 | $17.35 M(-10.5%) | $4.01 M(-1.1%) | $17.35 M(+0.9%) |
| Sept 2011 | - | $4.05 M(-10.5%) | $17.20 M(-4.9%) |
| June 2011 | - | $4.53 M(-4.6%) | $18.09 M(-6.9%) |
| Mar 2011 | - | $4.75 M(+23.1%) | $19.44 M(-3.8%) |
| Dec 2010 | $19.40 M(-13.6%) | $3.86 M(-22.0%) | $20.20 M(-15.1%) |
| Sept 2010 | - | $4.95 M(-15.8%) | $23.79 M(+1.6%) |
| June 2010 | - | $5.88 M(+6.5%) | $23.41 M(+1.4%) |
| Mar 2010 | - | $5.52 M(-25.9%) | $23.09 M(+2.9%) |
| Dec 2009 | $22.44 M(+3.8%) | $7.45 M(+63.0%) | $22.44 M(+7.9%) |
| Sept 2009 | - | $4.57 M(-17.7%) | $20.79 M(-0.6%) |
| June 2009 | - | $5.55 M(+13.9%) | $20.92 M(-1.5%) |
| Mar 2009 | - | $4.87 M(-16.0%) | $21.24 M(-3.0%) |
| Dec 2008 | $21.62 M(+4.3%) | $5.80 M(+23.6%) | $21.90 M(+2.1%) |
| Sept 2008 | - | $4.69 M(-20.2%) | $21.44 M(-1.8%) |
| June 2008 | - | $5.88 M(+6.3%) | $21.84 M(+4.2%) |
| Mar 2008 | - | $5.53 M(+3.4%) | $20.97 M(+1.1%) |
| Dec 2007 | $20.74 M(-2.8%) | $5.34 M(+5.0%) | $20.74 M(+1.4%) |
| Sept 2007 | - | $5.09 M(+1.7%) | $20.45 M(-1.1%) |
| June 2007 | - | $5.00 M(-5.6%) | $20.67 M(-3.1%) |
| Mar 2007 | - | $5.30 M(+4.8%) | $21.33 M(-0.0%) |
| Dec 2006 | $21.33 M(+17.4%) | $5.06 M(-4.7%) | $21.33 M(+3.6%) |
| Sept 2006 | - | $5.31 M(-6.3%) | $20.59 M(+3.2%) |
| June 2006 | - | $5.66 M(+6.8%) | $19.96 M(+4.8%) |
| Mar 2006 | - | $5.30 M(+22.8%) | $19.05 M(+4.8%) |
| Dec 2005 | $18.17 M(-2.3%) | $4.32 M(-7.6%) | $18.17 M(-0.2%) |
| Sept 2005 | - | $4.67 M(-1.6%) | $18.20 M(+0.6%) |
| June 2005 | - | $4.75 M(+7.2%) | $18.10 M(+0.6%) |
| Mar 2005 | - | $4.43 M(+1.9%) | $18.00 M(-3.3%) |
| Dec 2004 | $18.61 M(-19.9%) | $4.35 M(-4.9%) | $18.61 M(-6.7%) |
| Sept 2004 | - | $4.57 M(-1.5%) | $19.95 M(-5.6%) |
| June 2004 | - | $4.64 M(-8.0%) | $21.14 M(-5.9%) |
| Mar 2004 | - | $5.04 M(-11.4%) | $22.47 M(-3.3%) |
| Dec 2003 | $23.23 M(-0.0%) | $5.70 M(-1.0%) | $23.23 M(+0.9%) |
| Sept 2003 | - | $5.75 M(-3.7%) | $23.03 M(+0.0%) |
| June 2003 | - | $5.98 M(+3.0%) | $23.03 M(-0.2%) |
| Mar 2003 | - | $5.80 M(+5.6%) | $23.07 M(-0.7%) |
| Dec 2002 | $23.23 M(+11.4%) | $5.50 M(-4.5%) | $23.23 M(+1.7%) |
| Sept 2002 | - | $5.75 M(-4.5%) | $22.84 M(-2.9%) |
| June 2002 | - | $6.02 M(+0.8%) | $23.53 M(+4.3%) |
| Mar 2002 | - | $5.97 M(+16.9%) | $22.56 M(+8.1%) |
| Dec 2001 | $20.86 M(+14.1%) | $5.11 M(-20.7%) | $20.86 M(+88.1%) |
| Sept 2001 | - | $6.44 M(+27.6%) | $11.09 M(+15.1%) |
| June 2001 | - | $5.05 M(+18.1%) | $9.64 M(+3.0%) |
| Mar 2001 | - | $4.27 M(-191.6%) | $9.35 M(-48.9%) |
| Dec 2000 | $18.29 M(+530.7%) | -$4.66 M(-193.6%) | $18.29 M(-20.3%) |
| Sept 2000 | - | $4.98 M(+4.6%) | $22.95 M(+27.7%) |
| June 2000 | - | $4.76 M(-63.9%) | $17.97 M(+36.1%) |
| Mar 2000 | - | $13.21 M | $13.21 M |
| Dec 1999 | $2.90 M | - | - |
FAQ
- What is Lexicon Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals annual SG&A year-on-year change?
- What is Lexicon Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals quarterly SG&A year-on-year change?
- What is Lexicon Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals TTM SG&A year-on-year change?
What is Lexicon Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of LXRX is $113.98 M
What is the all time high annual SG&A for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high annual selling, general & administrative expenses is $113.98 M
What is Lexicon Pharmaceuticals annual SG&A year-on-year change?
Over the past year, LXRX annual selling, general & administrative expenses has changed by +$65.90 M (+137.05%)
What is Lexicon Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of LXRX is $39.59 M
What is the all time high quarterly SG&A for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $39.59 M
What is Lexicon Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, LXRX quarterly selling, general & administrative expenses has changed by +$7.36 M (+22.85%)
What is Lexicon Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of LXRX is -$7.38 B
What is the all time high TTM SG&A for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high TTM selling, general & administrative expenses is $143.45 M
What is Lexicon Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, LXRX TTM selling, general & administrative expenses has changed by -$7.48 B (-7657.66%)